Millipore licenses AGR2 mAb
November 04, 2010 | Thursday | News
Australian healthcare company, HealthLinx has signed a commercial
agreement to license its AGR2 monoclonal antibody (mAb) to Millipore.
The worldwide non-exclusive license agreement allows Millipore to
market and sell the monoclonal antibody for research purposes only,
with upfront fees and royalties to flow back to HealthLinx.
The second, multi-center, multi-national trial for HealthLinx’s OvPlex
ovarian cancer diagnostic blood test includes the testing of two
additional biomarkers, one of these being the recently identified AGR2.
It is anticipated that the inclusion of AGR2 in the multi-marker OvPlex
panel will increase its diagnostic performance, and the ability to
identify early stage cancers, and may aid in discriminating benign
masses from cancer.
Thermo Fisher forms scientific
advisory board
Thermo Fisher Scientific, a global biosupplier company, has formed a
Scientific Advisory Board to formalize the two-way exchange of
technological information between the company and representatives, from
some of the world’s premiere centers of health, science and education.
“Scientific discovery is often the catalyst for change. The insight and
distinct expertise of each member of our Scientific Advisory Board will
be invaluable in helping us set a course for the innovation of new
products and services that will meet the changing needs of our
customers,” said Marc N Casper, president & CEO, Thermo Fisher
Scientific.
